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ABSTRACT
Patients with advanced hepatocellular carcinoma (HCC)
have historically had few options and faced extremely
poor prognoses if their disease progressed after standard-
of-care tyrosine kinase inhibitors (TKIs). Recently, the
standard of care for HCC has been transformed as a
combination of the immune checkpoint inhibitor (ICI)
atezolizumab plus the anti-vascular endothelial growth
factor (VEGF) antibody bevacizumab was shown to
offer improved overall survival in the first-line setting.
Immunotherapy has demonstrated safety and efficacy
in later lines of therapy as well, and ongoing trials are
investigating novel combinations of ICIs and TKIs, in
addition to interventions earlier in the course of disease
or in combination with liver-directed therapies. Because
HCC usually develops against a background of cirrhosis,
immunotherapy for liver tumors is complex and oncologists
need to account for both immunological and hepatological
considerations when developing a treatment plan for their
patients. To provide guidance to the oncology community
on important concerns for the immunotherapeutic care
of HCC, the Society for Immunotherapy of Cancer (SITC)
convened a multidisciplinary panel of experts to develop a
clinical practice guideline (CPG). The expert panel drew on
the published literature as well as their clinical experience
to develop recommendations for healthcare professionals
on these important aspects of immunotherapeutic
treatment for HCC, including diagnosis and staging,
treatment planning, immune-related adverse events
(irAEs), and patient quality of life (QOL) considerations.
The evidence- and consensus-based recommendations
in this CPG are intended to give guidance to cancer care
providers treating patients with HCC.

INTRODUCTION
Hepatocellular carcinoma (HCC) is the most
common primary cancer of the liver and is
among the top causes of cancer-related death
worldwide.1 Mortality due to HCC exerts a
high human toll in most countries around the

world, and in the United States (US), the incidence has increased markedly in recent years.2
Risk factors for HCC are unevenly distributed
around the globe. In the USA, Europe, and
Japan, the predominant risk factors for HCC
related and obesity-
related
are overweight-
conditions, for example, non-alcoholic fatty
liver disease (NAFLD), as well as hepatitis C
virus (HCV), and alcohol abuse,3 whereas in
eastern Asia and sub-Saharan Africa hepatitis
B virus (HBV) is more prevalent as an etiological agent. Additional risk factors include
diabetes mellitus, obesity, exposure to aflatoxin B, hemachromatosis, and other hereditary disorders.4 5
Although curative interventions such as
liver transplant, surgery, and ablation may
offer favorable outcomes for patients with
early-
stage HCC, for many years options
were limited and prognosis was very poor
for advanced disease.6–8 The 2007 approval
of the multi-tyrosine kinase inhibitor (TKI),
sorafenib, for the first-
line treatment of
advanced HCC represented a breakthrough
as it was the first systemic therapy in several
decades to demonstrate improved survival
in liver cancer.9 However, despite several
additional approvals for TKIs including regorafenib10 and lenvantinib11 in the subsequent
years,12 the new modalities only offered incremental increases in overall survival (OS) for
patients with advanced HCC, until the advent
of immunotherapy and immune-
based
combination therapies.
In 2017, the US Food and Drug Administration (FDA) granted the first approval for
an immune checkpoint inhibitor (ICI) for
HCC. Nivolumab (targeting programmed
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harmonization. The recommendations within this guideline are meant to complement rather than supplant
sound clinical judgment, and their aim is to provide
clinicians with the most current thinking on integrating
immunotherapy into the treatment of patients with HCC.

GUIDELINE DEVELOPMENT METHODS
The Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines were used
as a model to develop the recommendations in this manuscript. IOM standards dictate that guideline development
is led by a multidisciplinary expert panel using a transparent process where both funding sources and conflicts
of interest are readily reported. This CPG is intended to
provide guidance and is not a substitute for the professional judgment of individual treating physicians.
Conflict of interest management
As outlined by IOM standards, all financial relationships
of expert panel members that might result in actual,
potential, or perceived conflicts of interest were individually reported. Disclosures were made prior to the onset
of manuscript development and updated on an annual
basis. In addition, panel members were asked to articulate any actual or potential conflicts at all key decision
points during guideline development, so that participants
would understand all possible influences, biases, and/
or the diversity of perspectives on the panel. Although
some degree of relationships with outside interests are
to be expected among experts, panel candidates with
significant financial connections that may compromise
their ability to fairly weigh evidence (either actual or
perceived) were not eligible to participate in guideline
development.
Recognizing that guideline panel members are among
the leading experts on the subject matter under consideration and guideline recommendations should have
the benefit of their expertize, any identified potential
conflicts of interests were managed as outlined in SITC’s
disclosure and conflict of interest resolution policies.
As noted in these policies, panel members disclosing a
real or perceived potential conflict of interest may be
permitted to participate in consideration and decision-
making of a matter related to that conflict, but only if
deemed appropriate after discussion and agreement by
the expert panel.
The financial support for the development of this
guideline was provided solely by SITC. No commercial
funding was received.
Recommendation development
Panel recommendations are based on literature evidence,
where possible, and clinical experience, where appropriate.19 Consensus for the recommendations here was
generated by open communication and scientific debate
in small-group and whole-group settings, surveying and
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794
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cell death protein 1 [PD-1]) monotherapy received accelerated approval based on a significant response rate and
prolonged duration of response (DOR) with manageable
side effects in patients who had previously been treated
with sorafenib.13 This was followed by encouraging data
for other ICIs—pembrolizumab (another anti-PD-1 ICI)
monotherapy14 and nivolumab in combination with the
cytotoxic T lymphocyte antigen-4 (CTLA-4) antagonist
ipilimumab15 —resulting in further accelerated approvals
by the FDA. The confirmatory phase III studies for single-
agent nivolumab and permbrolizumab, however, did not
meet their end points. In 2020, the anti-programmed
death-ligand 1 (PD-L1) antibody atezolizumab in combination with the anti-vascular endothelial growth factor
(VEGF) antibody bevacizumab16 gained full FDA approval
for first-line treatment of HCC on the basis of the phase III
study IMbrave150. This was the first regimen to demonstrate superiority to sorafenib in HCC since sorafenib’s
approval in 2007, in addition to being the first immunotherapy plus anti-VEGF combination to gain approval for
liver cancer. Additional trials are ongoing and the therapeutic landscape continues to evolve and expand.
HCC often develops on a background of chronic
inflammation, metabolic stress, cirrhosis, or fibrosis,
and thus, the use of immunotherapy in the setting of a
compromised liver is a complex but common challenge.
Although HCC is frequently an immunogenic cancer,
characterized by tumor-
infiltrating lymphocytes (TILs)
in the tumor microenvironment, the intratumoral milieu
has been shown to be generally immunosuppressive—in
part due to the acquired immune dysfunction that occurs
with cirrhosis, viral infection, or environmental insults
that contribute to disease development, but also partially
related to the liver’s intrinsic tolerogenicity.17 18 Despite
these hurdles, the incorporation of immunotherapy into
HCC care has offered more options to clinicians and has
extended survival considerably for a subset of patients.
The approval of immunotherapy agents for the treatment of HCC is relatively recent as compared with other
malignancies and experience with these new therapies is
still limited. Additionally, immunotherapy carries unique
considerations in many clinical aspects including patient
selection, management of immune-related adverse events
(irAEs), and evaluation of response to therapy compared
with other systemic treatments. To support the oncology
community and provide evidence- and consensus-based
recommendations on immunotherapy for HCC, the
Society for Immunotherapy of Cancer (SITC) convened
an international panel of experts to develop a new clinical practice guideline (CPG), covering topics including
recommended therapies, emerging agents, diagnostics
and biomarkers, monitoring response to treatment,
special patient populations, toxicity management, and
quality of life (QOL). Although the guideline focuses on
therapies approved by the FDA, the authors, as an international team, acknowledge that recommendations may
not fully align with approval or reimbursement policies
in other countries outside the US, and they encourage
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Level 1

Level 2

Level 3

Level 4

Level 5

Systematic review or
meta-analysis

Randomized trial or
observational study
with dramatic effect

Non-randomized,
controlled cohort, or
follow-up study

Case series, case-
Mechanism-based
control, or historically reasoning
controlled study

OCEBM, Oxford Centre for Evidence-Based Medicine.

responses to clinical questionnaires, as well as formal
voting in consensus meetings.
For transparency, a draft of this CPG was made publicly
available for comment during the development process
and prior to publication. All comments were evaluated
and considered for inclusion into the final manuscript
according to the IOM standard.
Evidence rating
The evidence- and consensus-
based recommendations
of the panel were refined throughout the development
process in order to obtain the highest possible agreement
among the experts, however, the minimum threshold was
defined as 75% approval among the voting members.
Evidence supporting panel recommendations was graded
according to the Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group ‘The
Oxford Levels of Evidence 2’ (2016 version). A summary
of the OCEBM grading scale may be found in table 1.
The level of evidence (LE) for a given recommendation is
expressed in parentheses following the recommendation
(eg, LE: 1). Recommendations without an associated LE
were based on expert consensus.
DIAGNOSTICS AND STAGING FOR PATIENTS WITH HCC
Initial HCC diagnosis
The initial diagnostic workup of HCC typically comprises
a histologic analysis of tumor samples obtained by biopsy
sectional imaging, a detailed analysis
or surgery, cross-
of the liver’s condition with laboratory studies, and an
assessment of the potential etiology of the HCC including
investigations of HBV and HCV viral status. Guidelines
for surveillance screening, initial diagnosis, and staging
of HCC have been developed by multiple organizations
including, but not limited to, the American Association
for the Study of Liver Diseases (AASLD),7 the American
College of Gastroenterology (AGC),20 the European
Society for Medical Oncology (ESMO),21 the European
Association for the Study of the Liver (EASL)22 and the
Japan Society of Hepatology (JSH).23 These organizations and others have also put forth guidelines for non-
immunotherapeutic approaches for the treatment of
HCC.
HCC may be identified using computerized tomography (CT) and magnetic resonance imaging (MRI)
with Liver Imaging Reporting And Data Systems (LI-
RADS).24 The LI-RADS system provides a standardized
approach for radiologists to communicate with the
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794

treating physicians and provides a certain level of confidence that a lesion in a cirrhotic liver or a liver at risk for
cirrhosis presents as HCC on imaging.25 LI-RADS staging
ranges from LR-1, for lesions that are definitely benign, to
LR-5, which represents 100% probability of being HCC.
The LI-RADS system acknowledges that limitations exist,
and has included an LR-NC (for non-categorizable) category where diagnostic possibilities cannot be meaningfully narrowed. LI-RADS is endorsed by the AASLD,7 as
well as by the Organ Procurement and Transplantation
Network (OPTN)/United Network for Organ Sharing
(UNOS). Contrast agents have also greatly enhanced the
diagnostic accuracy of MRIs. Multiple meta-analyses have
determined that gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced
MRI has superior sensitivity, specificity, and diagnostic
odds ratio (OR) as compared with multidetector CT.26–28
However, most published guidelines do not recommend
one imaging modality over the other.
Patients with HCC often present with underlying
cirrhosis—two conditions with independent mortality
risks. It is essential for a care team comprised of multiple
specialties, including perspectives from both hepatology
and oncology, to be established early so that a treatment
plan that addresses all of the complex needs of a patient
with HCC may be developed.29 A multidisciplinary tumor
board review of liver lesions is recommended for HCC
diagnosis and management plans, particularly for patients
with tumors that may be eligible for transplant, surgery,
or liver-directed treatments.
Historically, avoiding tumor biopsy has been acceptable
practice in patients with cirrhosis and imaging characteristics consistent with HCC. One concern of performing
biopsies in this disease has been the putative risk for
tumor dissemination outside the liver via needle track
seeding. The occurrence of needle track seeding appears
to be uncommon in the published literature, however,
with incidence rates estimated to be as low as 2.7% overall,
or 0.9% per year.30 While biopsy may be less encouraged
in certain clinical scenarios such as in patients where liver
transplants are being considered, histologic diagnosis
is increasingly encouraged for the diagnosis of HCC,
particularly for more advanced tumors requiring systemic
therapy. Other primary liver tumors such as cholangiocarcinoma or mixed cholangiohepatoma can occasionally present very similarly to HCC, and the treatment for
these tumors can be distinct. Other entities such as metastatic neuroendocrine cancers can similarly demonstrate
3
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Table 1 Summary of ‘The Oxford Levels of Evidence 2’ (Adapted from the OCEBM Levels of Evidence Working Group)
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Stage Definition
0
1

No HCC
One HCC <20 mm

2

One HCC ≥20 mm and ≤50 mm, or two or three
HCCs, all ≤30 mm

3

One HCC >50 mm, or two or three HCCs, at least
one >30 mm
4A. Four or more HCCs, regardless of size
4B. HCC + TIV

4

HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting
And Data System; OPTN/UNOS, Organ Procurement and
Transplantation Network/United Network for Organ Sharing; TIV,
tumor in vein.

arterial enhancement on multiphase imaging.31 Additionally, in rare instances, tissue biopsy may uncover
certain genetic alterations that render a patient eligible
for a tissue-agnostic therapy or a clinical trial.
HCC staging
An ideal staging system in HCC serves two purposes: treatment indication and prognostic prediction. A variety of
staging systems have been developed, and their performance and validation varies. While some staging systems
focus on pathology, others incorporate radiological characteristics, serum biomarkers, liver function, and performance status. In most solid tumors, staging is performed
at the time of surgery using resected specimens. The
Tumor-Node-Metastases (TNM) classification, developed
by the American Joint Committee on Cancer (AJCC), classifies the primary tumor (T) based on size, number, and
vascular invasion.32 However, the TNM classification is not
currently used to guide treatment for HCC. Also, importantly, the TNM classification should not be confused
with the radiologic T-staging system used by LI-RADS and
OPTN/UNOS, which is summarized in table 2.
Radiographic T-staging is of limited pretreatment prognostic and predictive value for patients being considered for systemic therapy, as the system does not take
into account liver function, which is an important risk
factor for patients with HCC. Several alternative staging
or scoring systems have been developed, including the
Barcelona-Clinic Liver Cancer (BCLC) system,33 Cancer
of the Liver Italian Program (CLIP),34 Japan Integrated
Staging (JIS),35 Chinese University Prognostic Index
(CUPI),36 Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GETCH)37 plus many others.
The BCLC system, summarized in table 3, has gained
wide recognition and has been endorsed by multiple
international hepatology associations including AASLD6
and EASL. Several large-scale cohort studies have validated the BCLC system, including in Korean patients
with treatment‐naïve HCC,38 US patients,39 and Italian
patients undergoing radical surgery.40 In addition, scoring
4

Table 3 Barcelona-Clínic Liver Cancer (BCLC)
classification with stage definitions and typical survival
outcomes
Stage definition
Estimated
(BCLC 2018 update) survival
Stage 0—Very
early-stage

Stage A—Early-
stage

Single nodule ≤2 cm;
ECOG PS 0*;
Preserved liver
function
Single or up to three
nodules ≤3 cm;
ECOG PS 0*;
Preserved liver
function

>5 years

>5 years

Stage B—
Multinodular;
Intermediate-stage ECOG PS 0*;
Preserved liver
function

>2 to 5 years

Stage C—
Advanced-stage

>1 year

Portal invasion;
Extrahepatic spread;
ECOG PS 1–2;
Preserved liver
function
Stage D—Terminal- ECOG PS 3–4;
stage
End-stage liver
function

3 months

*The American Association for the Study of Liver Disease (AASLD)
recommends including ECOG PS 0 to 1 in stage 0, A and B,
because of the significant overlap between PS 0 and PS 1
BCLC, Barcelona-Clinic Liver Cancer; ECOG, Eastern Cooperative
Oncology Group; PS, performance status.

by the BCLC system has been reported and studied in
subgroup analyses for most of the phase III studies done
in advanced HCC.
HCC is a highly heterogeneous disease with varied
underlying etiologies depending on geography and
demographics. Studies comparing the performance of
staging systems for predicting prognosis have returned
conflicting results depending on the patient population
investigated and the treatments administered. The JIS
score showed the best ability to predict OS by disease stage
in an analysis of Japanese patients,41 whereas an analysis
of 1,713 prospectively enrolled patients with HCC in
Taiwan found that CLIP was the best prognostic model in
patients undergoing both curative and non-curative treatments.42 In the advanced and metastatic disease setting,
another comparison of the prognostic value of different
systems determined CLIP and CUPI to be the most reliable staging systems for patients with HCV and HBV etiologies, respectively.43 In these analyses of patients with
advanced disease in need for systemic therapy, BCLC and
TNM lacked prognostic value.
Liver function assessment is a critical component of
HCC treatment that is required for every patient. Some
of the staging systems embed within them the Child-Pugh
classification, recognizing the need for assessing the
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794
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Diagnostic biomarkers
Several biomarkers have been put forward to predict
prognosis in HCC, yet none are currently routinely used
to guide treatment decisions for patients being considered for immunotherapy. Serum alpha-fetoprotein (AFP)
has been the most widely used marker to increase the
suspicion for a diagnosis of HCC, and has been included
in international guidelines.21 51 However, the value of
AFP as a surveillance marker remains controversial,52 and
establishing a threshold value to diagnose HCC remains
a challenge.52 53 Tumor-derived AFP has also been implicated in impaired dendritic cell function.54 Glypican 3
(GPC3), an antigen that is highly expressed on tumor
cells and minimally present on healthy tissues,55 has been
proposed as a serum biomarker for HCC and is being
pursued as a target for chimeric antigen receptor (CAR)
T cell therapies.56 However, neither AFP nor GPC3 have
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794

demonstrated predictive power for patients being treated
with ICIs, although this is an active area of research.
The GALAD score, which determines risk of HCC based
on patient sex, age, and serum levels of AFP, AFP isoform L3,
and des-gamma-carboxy prothrombin has been validated
for detection of HCC in patients with non-alcoholic steatohepatitis (NASH) with and without cirrhosis.57 A combination of GALAD and ultrasound (GALADUS) score has
been shown to further improve performance, with an area
under the curve of 0.98 (95% CI 0.96 to 0.99; cut-off −0.18;
sensitivity 95%; specificity 91%) in a single-center cohort
of 111 patients with HCC and 180 controls with cirrhosis or
chronic HBV.58 In March of 2020, the FDA granted breakthrough device designation to the Elecsys GALAD score
to aid in early diagnosis of HCC (for further discussion
of immunotherapy-specific biomarkers, including PD-L1
status, see the Patient selection and management section).
Panel recommendations
►► A multidisciplinary tumor board review of liver lesions
is recommended for HCC diagnosis and the development of a management plan.
►► Notwithstanding that LI-
RADS-5 is nearly 100%
specific for HCC (LE: 1), histologic confirmation is
recommended for patients with unresectable disease
particularly prior to the initiation of systemic therapy.
Histologic diagnosis is mandatory for non-cirrhotic
patients.
►► Despite the controversy regarding the scoring and
staging systems that could be used, before initiation
of systemic therapy, an evaluation of liver function,
including aspartate transaminase (AST)/alanine
aminotransferase (ALT), bilirubin, prothrombin time
(PT)/international normalized ratio (INR), albumin,
plus platelets, is critical (LE: 2).
►► For patients being considered for immunotherapy, an
HCC-specific staging system incorporating liver function assessment is suggested (LE: 2).
►► To evaluate patients prior to receiving immunotherapy, Child-Pugh classification would be the most
appropriate to date (LE: 1) to measure liver function.
RECOMMENDED IMMUNOTHERAPIES FOR HCC
Available agents and indications
For more than 10 years, sorafenib was the only systemic
therapy approved by the FDA for the treatment of HCC.
Since 2017, four ICI regimens have entered the clinic
after having received full or accelerated approval by
the FDA for the treatment of advanced HCC. Only one
combination, atezolizumab with bevacizumab, had full
FDA approval at the time of guideline preparation, the
remaining regimens (nivolumab and pembrolizumab
monotherapy and nivolumab with ipilimumab) received
accelerated approvals, and FDA review of confirmatory
trials is ongoing. Results of the landmark trials leading to
these approvals are described in table 4. Further details
for each indication are discussed in chronological order
of their FDA approvals.
5

J Immunother Cancer: first published as 10.1136/jitc-2021-002794 on 12 September 2021. Downloaded from http://jitc.bmj.com/ on October 6, 2021 by guest. Protected by copyright.

extent of liver functionality as part of the staging of the
disease. The Child-Pugh score evolved over time from the
original system built in 1973 to help assess for survival of
patients with bleeding esophageal varices.44 Of note, in
the original Pugh effort, none of the patients had HCC.
The system evolved into a five-parameter staging system
which consists of three laboratory values (serum albumin,
bilirubin, and prothrombin levels) and two clinically
assessed variables (presence and degree of ascites and
hepatic encephalopathy). A final score ranging from 5 to
15 is calculated based on the range of laboratory values
and severity of clinical symptoms, and then classified into
one of three classes: A (5–6), B (7–9), and C (10–15).44 45
Median survival of untreated HCC has been shown to
be approximately 2.5 times lower in patients with Child-
Pugh B disease compared with those with Child‐Pugh
A.46 Recently, however, the limitations and subjectivity
involved in the grading of clinical variables have called
into question Child-Pugh scores in assessing liver function in HCC.47
The albumin-bilirubin (ALBI) grade, a simpler model
to assess liver function based only on serum albumin
and bilirubin, has been validated in study cohorts
from multiple geographic regions and multiple clinical scenarios, including patients undergoing resection and sorafenib treatment. The score is calculated
as (log10 bilirubin [µmol/L]×0.66) + (albumin [g/L] ×
−0.0852), leading to three possible grades: ALBI Score
≤ −2.60 (ALBI grade 1), ALBI Score > −2.60 to ≤ −1.39
(ALBI grade 2), and ALBI Score > −1.39 (ALBI grade
3).48 The ALBI grade demonstrated superior prognostic
value to the Child-Pugh score in a study of patients with
HCC treated with radioembolization, particularly within
patients with Child-Pugh A disease.49 ALBI grade also
predicts OS after surgical resection (p<0.001), transarterial chemoembolization (TACE) (p<0.001) and sorafenib
treatment (p<0.001), with independent prognostic value
across BCLC stages, geographic regions (p<0.001),50 and
for cancers being treated with immunotherapy.50

Open access

Trial (NCT#)

Phase

Agent(s) evaluated

Study population

Patients

Outcomes

CheckMate 040
(NCT01658878)

I/II

Nivolumab*†

Patients with histologically 262
confirmed advanced HCC
with or without HCV or
HBV infection. Previous
sorafenib treatment was
allowed. CP A or B7
disease for dose escalation;
CP A disease for dose
expansion.

ORR 20%
(95% CI 15% to 26%) in
dose-expansion phase
ORR 14.3%
(95% CI 6% to 28%) in
population with progressive
disease on/intolerance to
sorafenib

KEYNOTE-224
(NCT02702414)

I

Pembrolizumab*

Patients with disease
progression on or after
sorafenib or intolerant to
sorafenib, and measurable
CP A disease.

104

ORR 17%
(95% CI 11% to 26%)

CheckMate 040
(NCT01658878)

I/II

Nivolumab+ipilimumab*

Patients with histologically
confirmed advanced HCC
with or without HCV or
HBV infection. Previous
sorafenib treatment was
allowed.

148

ORR 33%
(95% CI 20% to 48%)

IMbrave150‡

III

Atezolizumab+
bevacizumab vs sorafenib

Patients with unresectable 501
HCC who had received no
prior systemic therapy and
had well-compensated liver
disease.

OS HR 0.58 (95% CI 0.42
to 0.79; p<0.001)
ORR 27.3% vs 11.9%
(p<0.001)

*Accelerated approval contingent on confirmatory trials
†Indication voluntarily withdrawn July 2021
‡Updated data with 12 additional months of follow-up found ORR of 29.8% (95% CI 24.8% to 35.0%) for atezolizumab+bevacizumab versus 11.3%
(95% CI 6.9% to 17.3%) for sorafenib66
CI, confidence interval; CP, Child-Pugh; FDA, US Food and Drug Administration; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HR, hazard ratio; ORR, overall response rate; OS, overall survival.

Prior sorafenib therapy
In 2017, nivolumab received accelerated approval as
monotherapy for the treatment of patients with HCC
with progression following or intolerance to sorafenib.
Approval was based on data from a cohort of patients
from the CheckMate 040 Trial, a phase I/II, open-label,
multicenter study. Among the 154 patients treated with
nivolumab, 22 (14.3%; 95% CI 9.2% to 20.8%) had an
objective radiologic response based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Three patients (1.9%) had complete responses (CRs)
and 19 (12.3%) had partial responses (PRs). DORs
ranged from 3.2 months to 38.2+ months with 91%
lasting 6 months or longer and 55% lasting 12 months
or longer. The overall response rate (ORR), based on
modified RECIST (mRECIST), was 18.2% (28 patients;
95% CI 12.4% to 25.2%) and the CR rate was 3.2%
(5 patients) with a PR rate of 14.9% (23 patients). No
differences in response rates were observed across PD-L1
expression levels.13 Postregistration studies support the
safety of single-agent nivolumab in patients with Child-
Pugh B disease59 where treatment is associated with
shorter OS compared with Child-
Pugh A disease (7.3
months vs 16.3 months; p<0.001).60 Data from cohort 5
of CheckMate 040, which included 25 sorafenib-
naïve
6

and 24 sorafenib-treated patients with Child-Pugh B7-B8
advanced HCC, also showed safety and efficacy for single-
agent nivolumab in a setting of mild to moderate liver
impairment61 (for further details on immunotherapy in
special patient populations, see the Patient selection and
management section). Continued accelerated approval
for nivolumab monotherapy was contingent on the
confirmatory trial CheckMate 459 (described below).
On March 10, 2020, nivolumab in combination with
ipilimumab received accelerated approval by the FDA
to treat patients with HCC who were previously treated
with sorafenib. Approval was based on the results of an
additional cohort (cohort 415) from CheckMate 040. In
the CheckMate 040 cohort 4, 148 patients were randomized 1:1:1 to three different treatment arms to evaluate
different dosing regimens of the combination: high-
dose ipilimumab, low-dose ipilimumab and continuous
nivolumab/ipilimumab for arms A, B, and C, respectively.
For approval, efficacy was evaluated in the 49 patients
who received nivolumab at 1 mg/kg and ipilimumab at
3 mg/kg every 3 weeks for 4 doses, followed by single-
agent nivolumab every 2 weeks until disease progression
or unacceptable toxicity. Data from all arms support
anti-
HCC activity of the regimen, however. The ORR
reported for accelerated approval was 33% (n=16; 95% CI
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Of the responders, 89% had a DOR ≥6 months, and 56%
had a DOR ≥12 months.14
The phase III KEYNOTE-240 confirmatory trial evaluating pembrolizumab versus placebo was negative based
on the co-primary end point of median OS and PFS.
Median OS was 13.9 months (95% CI 11.6 to 16.0) for
pembrolizumab versus 10.6 months (95% CI 8.3 to 13.5)
for placebo (HR 0.781; 95% CI 0.611 to 0.998; p=0.0238),
and median PFS for pembrolizumab was 3.0 months
(95% CI 2.8 to 4.1) versus 2.8 months (95% CI 1.6 to
3.0; HR 0.718; 95% CI 0.570 to 0.904; p=0.0022), but this
did not meet statistical significance by the prespecified
statistical plan.65 The study did confirm the single-agent
response rate of pembrolizumab in this setting with an
ORR of 18.3 (95% CI 14.0 to 23.4) and a DOR of 13.8
months (range 1.5–23.6+ months). Despite the confirmatory trial not meeting prespecified end points, when the
FDA ODAC reviewed the accelerated approval in April
2021 the vote to maintain the indication for pembrolizumab was unanimous, citing unmet medical need for
patients who cannot receive first-line atezolizumab with
bevacizumab (described below) and who have disease
progression with or become intolerant to TKIs.
First-line therapy
The first ICI regimen to receive full approval and the
first to receive first-line approval for the treatment of
HCC is atezolizumab in combination with bevacizumab
for patients who have not received prior systemic therapy,
which was approved in 2020. Approval was based on the
global, open-label, phase III IMbrave150 trial, in which 501
patients with unresectable HCC were randomly assigned
in a 2:1 ratio to receive either first-line atezolizumab plus
bevacizumab or sorafenib monotherapy until unacceptable toxic effects or loss of clinical benefit occurred. At
the primary analysis, the HR for death with atezolizumab
plus bevacizumab compared with sorafenib was 0.58
(95% CI 0.42 to 0.79; p<0.001). The 12-month OS rate
was 67.2% (95% CI 61.3% to 73.1%) with atezolizumab
plus bevacizumab and 54.6% (95% CI 45.2% to 64.0%)
with sorafenib. Median PFS was 6.8 months (95% CI 5.7
to 8.3) versus 4.3 months (95% CI 4.0 to 5.6) with atezolizumab plus bevacizumab versus sorafenib, respectively
(HR for disease progression or death 0.59; 95% CI 0.47
to 0.76; p<0.001).16 In an updated post hoc survival analyses, median OS was 19.2 months with atezolizumab plus
bevacizumab compared with 13.4 months with sorafenib
(HR 0.66; 95% CI 0.52 to 0.85; p=0.0009). The OS rates
at 18 months were 52% vs 40% with atezolizumab plus
bevacizumab versus sorafenib, respectively.66
The combination therapy also delayed deterioration
in QOL compared with sorafenib monotherapy. In terms
of the tolerability profile, grade 3–4 adverse events (AEs)
occurred in 57% of patients treated with atezolizumab
with bevacizumab.16 Additionally, the development of
anti-drug antibodies (ADAs) is a possibility in patients
treated with atezolizumab.67 In IMbrave150, among 318
ADA-
evaluable patients with HCC, 30% (n=94) tested
7
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20% to 48%), with 4 CRs and 12 PRs. DORs ranged from
4.6 months to 30.5+ months, with 31% of responses lasting
24 months or longer.62 An updated analysis at a minimum
follow-up of 44 months found ORRs by blinded independent central review of 32%, 31%, and 31% for arms A,
B, and C, respectively. Median DORs were 17.5 months,
22.2 months, and 16.6 months for arms A, B, and C, and
median OS for each arm was 22.2 months, 12.5 months,
and 12.7 months, respectively.63
In CheckMate 459, a phase III trial evaluating the
efficacy of nivolumab as a first-
line monotherapy, the
ORR was 15% in the nivolumab group and 7% in the
group receiving sorafenib. Median OS was 16.4 months
for nivolumab-
treated patients and 14.7 months for
sorafenib-treated patients (HR 0.85; 95% CI 0.72 to 1.02;
p=0.0752). The difference in OS between the two groups
did not meet prespecified thresholds for statistical significance (HR 0.84; p=0.0419).64 Nevertheless, nivolumab
demonstrated a favorable safety profile, better response
rate, improved tolerability, and better QOL outcomes
when compared with sorafenib. A trend towards better
survival and response rate was noted in patients with
PD-L1 tumor proportion score (TPS) ≥1% (about 19% of
the randomized subjects) measured by the Dako PD-L1
immunohistochemistry (IHC) assay, supporting the
importance of predictive biomarker development. In a
4:5 vote, the FDA Oncologic Drugs Advisory Committee
(ODAC) recommended rescinding the indication for
nivolumab for the treatment of patients with HCC and
prior sorafenib therapy. There was unanimous agreement
from committee members that voting was difficult due to
the many factors, including the earlier vote to maintain
the indication for pembrolizumab monotherapy. Those
in favor of continued accelerated approval for nivolumab
in this patient population highlighted the unmet need
for second-line options. Rationale against continuing the
indication centered on the lack of OS benefit in CheckMate 459 and the inadequacy of the proposed alternative studies to generate satisfactory evidence for efficacy
in the second-line setting. Discussion also narrowed in
on whether data exist to recommend nivolumab monotherapy over an ipilimumab plus nivolumab combination regimen, including debate over whether the group
of patients deemed unfit for the dual checkpoint inhibitor combination represent a new indication that was not
formally defined nor evaluated in trials to date. In July
2021, the nivolumab monotherapy indication for HCC
was voluntarily withdrawn.
Accelerated approval was granted to pembrolizumab in
2018 for patients with HCC who have previously received
sorafenib based on results from the phase II KEYNOTE224 Trial. The study enrolled 104 patients to receive
agent pembrolizumab with advanced HCC and
single-
radiographic progression or intolerance to sorafenib.
The ORR was 17% (95% CI 11% to 26%) and among the
18 patients who responded, there was 1 CR and 17 PRs. At
data cut-off, 12 of the 18 responses were ongoing and the
median DOR was not reached (range 3.1–14.6+ months).
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Panel recommendations
For first-
line treatment of patients with advanced
Child-Pugh A HCC, atezolizumab plus bevacizumab is
recommended, unless either medication is contraindicated (LE: 2).
►► General contraindications to bevacizumab include
high risk of cardiac disease, stroke, hemorrhage,
hemoptysis, gastrointestinal perforation, or non-
healing wounds (LE: 1). (For contraindications
to immunotherapy, see the Patient selection and
management section). Consideration should be given
to timing of prior events. Additional contraindications specifically relevant to HCC include untreated
or incompletely treated gastroesophageal varices at
risk for bleeding (LE: 2).
►► For patients with contraindications to atezolizumab
plus bevacizumab treatment, lenvatinib or sorafenib
should be considered as standard first-line therapy
(LE: 2).
►► Nivolumab monotherapy has demonstrated activity in
Child-Pugh B7-B8 HCC for both first-line treatment
of sorafenib-naïve patients and for second-line treatment of patients who were intolerant to or progressed
on sorafenib (LE: 3).
►► For patients with good performance status who have
progressed on first-line therapy and have not received
prior immunotherapy, other non FDA-approved or
conditionally approved anti-
PD-1 checkpoint inhibitors may be considered as immunotherapeutic
options (LE: 3).
►►

IMMUNOTHERAPIES IN DEVELOPMENT FOR HCC
The potential benefit of ICIs as monotherapies or in
combination regimens including other ICIs or anti-
VEGF agents for advanced HCC is being evaluated in
several ongoing trials. Additionally, mechanistic rationale supports the integration of ICIs with locoregional
therapies for disease in early stages, and some studies
have reported tolerable safety with evidence for efficacy
with the combination of checkpoint blockade and liver-
directed therapy. Finally, the development of novel strategies such as vaccines or adoptive cell therapies is an active
area of investigation, although still in early stages at the
time of publication.
Checkpoint inhibitors and novel combinations
Tremelimumab, an anti-CTLA-4 ICI, has been evaluated
in a pilot trial of patients with HCC with chronic HCV
infection. Among the 17 patients who were assessable
8

for tumor response, the PR rate was 17.6% and disease
control rate (DCR) was 76.4% with a median time to
progression of 6.48 months (95% CI 3.95 to 9.14). Significant drops in viral load were observed in the 20 patients
who were evaluable for toxicity and viral responses, and
no patients needed steroids because of severe irAEs.69
Single-agent tislelizumab (anti-PD-1),70 camrelizumab
(anti-PD-1),71 and durvalumab (anti-PD-L1)72 are all also
being studied in phase III trials.
Combination ICI regimens are also under investigation. The FDA has approved nivolumab at 1 mg/kg with
ipilimumab at 3 mg/kg regimen as a second-line treatment option for patients with prior sorafenib exposure.73
Recently, another combination regimen, durvalumab in
combination with tremelimumab, reported an ORR of
up to 22.7% and a median OS of up to 18.7 months in
the advanced HCC population using one single dose of
tremelimumab at 300 mg, with further enhancement of
response among patients with CD8+ Ki67+ proliferative T
cells.74 The phase III HIMALAYA trial investigating one
single dose of tremelimumab with durvalumab as first-line
treatment in patients with unresectable HCC is ongoing75
and this combination regimen has been granted orphan
drug designation by the FDA.
In the CheckMate 040 trial cohort 6,76 the efficacy and
safety profile of the triplet combination of cabozantinib,
nivolumab, and ipilimumab were analyzed and compared
with the cabozantinib plus nivolumab doublet. A total
of 71 sorafenib-naïve or sorafenib-experienced patients
with advanced HCC were randomized to either receive
nivolumab 240 mg every 2 weeks with cabozantinib
40 mg daily (n=36) or nivolumab 3 mg/kg every 2 weeks
with ipilimumab 1 mg/kg every 6 weeks and cabozantinib 40 mg daily (n=35). Although the study was not
powered to directly compare efficacy of the triplet versus
doublet regimens, numerically higher response rates
(29% vs 19%), better PFS (median 6.8 vs 5.4 months)
and improved median OS (not reached vs 21.5 months;
15-month OS rates: 70% vs 64%) were observed with the
three-drug combination. Nevertheless, a higher rate of
treatment-emergent AEs was also observed in the triplet
arm, without the emergence of new safety signals in either
treatment arms.
HCC is one of the most vascularized solid tumors and
anti-
angiogenic agents may complement immunotherapies. Multiple anti-
angiogenic multikinase inhibitors
are being evaluated in combination with checkpoint
inhibitors for HCC. The combination with the most
available data at the time of manuscript preparation is
pembrolizumab plus lenvatinib. In Study 116, an ongoing
phase Ib multicenter open-label study of lenvatinib plus
pembrolizumab in 104 patients with unresectable HCC,
the confirmed ORRs at data cut-off were 46.0% (95%
CI 36.0% to 56.3%) by mRECIST and 36.0% (95% CI
26.6% to 46.2%) by RECIST v1.1 with median DORs
of 8.6 months (95% CI 6.9 to not estimable [NE]) and
12.6 months (95% CI 6.9 to NE), respectively. Median
OS was 22 months and treatment-related AEs of grade
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positive for treatment-emergent ADAs at one or more
post-dose time points. In exploratory adjusted analyses,
patients who were ADA-positive at landmark week 6 had
a similar OS with atezolizumab plus bevacizumab versus
sorafenib, whereas those with ADA-negative status had an
improved OS compared with sorafenib. However, similar
PFS and ORR benefit was seen with the combination over
sorafenib regardless of ADA status.68
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Integration with local and regional therapies
Locoregional therapies such as TACE and drug-eluting
bead TACE (DEB-
TACE) may induce immunogenic
cell death, thus promoting CD8+ T cell infiltration into
the tumor microenvironment, potentially synergizing
with anti-PD-(L)1 therapy.81 Doxorubicin, which has
been shown to cause immunogenic cell death,82 is the
most commonly administered drug during TACE and
DEB-
TACE, and patients undergoing chemoembolization have been shown to develop AFP-specific CD4+ T
cell responses83 as well as GPC3-specific cytotoxic T cell
responses.84
A few studies have reported tolerable safety and initial
efficacy outcomes with the combination of ICIs and
locoregional therapies such as TACE and radiofrequency
ablation (RFA). One trial enrolled 32 patients with HCC
for tremelimumab therapy at two dose levels (3.5 mg/
kg and 10 mg/kg intravenous [IV]) every 4 weeks for
6 doses, followed by infusions every 3 months until off-
treatment criteria were met. On day 36, patients underwent subtotal RFA or chemoablation. Of the 19 evaluable
patients, 5 (26.3%; 95% CI 9.1% to 51.2%) achieved PR.
The median time to tumor progression was 7.4 months
(95% CI 4.7 to 19.4) and median OS was 12.3 months
(95% CI 9.3 to 15.4).85
Integration with transplant
Checkpoint inhibitors are considered contraindicated in
patients undergoing transplantation due to fears of graft
rejection.86 Reports have emerged of immunotherapy
being used as salvage therapy in liver transplant recipients with malignancies other than HCC, but rejection was
frequent. A review of 14 cases of liver transplant recipients
who were treated with ICIs identified four cases of liver
graft rejection and three cases with lethal outcomes.87
Another retrospective study including 39 patients with
solid organ transplants reported permanent discontinuation of ICIs in 31% because of allograft rejection. Graft
loss occurred in 81%, leading to death in 46%.88
Vaccines
Some vaccines have demonstrated manageable safety and
preliminary efficacy in early phase trials in HCC. Although
no antitumor effects or immune responses were detected
among 40 patients with advanced HCC who were treated
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794

with low-dose cyclophosphamide in combination with a
telomerase peptide vaccine (GV1001),89 other strategies
have posted more promising results.
Several groups have attempted to develop peptide
vaccines based on GPC3. One GPC3 peptide vaccine was
well tolerated in a phase I trial that included 33 patients
with advanced HCC. Vaccination induced a GPC3-specific
cytotoxic T lymphocyte response in 90% of patients—
there was 1 PR and 19 cases of stable disease at 2 months.90
That same vaccine was shown to lead to numerically lower
rates of recurrence compared with surgery alone at 1 year
(28.6% vs 54.3%) and 2 years (39.4% vs 54.5%) in the
adjuvant setting in a phase II trial of 35 patients with HCC
who had undergone resection.91
AFP-based vaccines have been shown to elicit T cell
responses in early trials. Four immunodominant, human
leukocyte antigen (HLA)-A*0201-restricted epitopes of
AFP that are recognized by the human T cell repertoire
have been identified.92 In a pilot phase I clinical trial that
enrolled six HLA-A*0201 patients with AFP-positive HCC
for intradermal vaccinations with the four peptides emulsified in incomplete Freund’s adjuvant, T cell responses
were observed against most or all of the epitopes.93 Subsequently, a phase I/II trial that included 10 HLA-A*0201
patients with AFP-positive HCC who were immunized with
intradermal vaccinations of the four AFP peptides pulsed
onto autologous dendritic cells found statistically significant levels of AFP-specific T cells to at least one peptide
by major histocompatibility complex (MHC) tetramer in
60% of participants.94
Tumor lysate-based vaccines have also been evaluated
in HCC. One study found that autologous tumor vaccination significantly delayed time to recurrence in 60
patients with HCC who had undergone curative resection. The 1-year, 2-year and 3-year recurrence rates in the
30 patients in the vaccine group were 16.7%, 29.2%, and
33.3%, respectively, compared with 30.8%, 53.8%, and
61.5%, respectively, in the control group.95 Another phase
II trial of autologous dendritic cells pulsed with tumor
lysate observed a radiologically determined DCR of 28%
in 35 patients with advanced HCC.96 Hepcortespenlisimut-L, a tableted oral formulation derived from a heat-
inactivated pooled blood of patients with HCC and viral
hepatitis, has entered phase III trials in patients with
HCC and demonstrated clear improvements in ALT, AST,
alkaline phosphatase, and bilirubin levels compared with
placebo.97
The dramatically high efficacy rates seen with RNA-
based vaccines during the COVID-19 pandemic has re-invigorated the study of RNA-vaccinology—a concept with
roots in the immunotherapy discipline.98 99 RNA has been
used as both a vaccine platform and an adjuvant to boost
immunogenicity for HCC-specific epitopes, such as HLA-
A*02-restricted tumor-associated peptides.100 101
Adoptive cell therapies
To date, the most advanced clinical studies for cellular
therapies in HCC are with cytokine-induced killer cells
9
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≥3 occurred in 67% of patients.77 The ongoing phase
III LEAP‐002 trial is also studying the combination and
enrolling patients for treatment with pembrolizumab
plus lenvatinib for first-line treatment of advanced HCC.78
Other ICI/TKI combination studies include avelumab
with axitinib, which led to tumor shrinkage in 15 (68.2%)
and 16 (72.7%) patients and an ORR of 13.6% (95% CI
2.9% to 34.9%) and 31.8% (95% CI 13.9% to 54.9%)
by RECIST and mRECIST, respectively in one study.79
Cabozantinib is being combined with atezolizumab for
patients who have not received prior systemic therapy for
HCC in the phase III study COSMIC‐312.80
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Panel recommendations
Clinicians should encourage patients' participation in
clinical trials.
►► Future biomarker development might help to select
a subgroup of patients benefitting from single-agent
nivolumab treatment. Designing a biomarker strategy
based on pretreatment and on-treatment tissue and
blood samples to assess immune cell changes and
other correlatives is critical to elucidate mechanisms
of response or resistance to immunotherapy in combination with local therapy in early-stage HCC.
►► Studies evaluating combinations of other immunotherapies with ICIs should be based on solid scientific
rationale.
►► Future randomized studies to compare local therapy
alone to local therapy combined with immunotherapy are essential to assess the expected synergy
and favorable treatment outcome of the combination
strategy.
►►

PATIENT SELECTION AND MANAGEMENT
Patient selection
In selecting the appropriate patient for consideration
of treatment with a standard immunotherapy-
based
approach (as opposed to within the context of a clinical
trial), there are both general oncologic considerations
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as well as HCC-specific or liver-specific considerations. It
is critical to account for the singular nature of HCC, as
it generally arises in a damaged and potentially dysfunctional liver. As many as 43% of patients with HCC will die
as a direct result of cirrhosis as opposed to cancer progression.108 Therefore, clinical trials needed for patients with
more advanced liver function decompensation than
Child-Pugh B7 are encouraged, especially when the main
factor behind liver function deterioration is HCC progression rather than the underlying liver disease. Additional
considerations include the patient’s performance status
and history of comorbidities, in particular the presence of
any known autoimmune disorders. A patient’s eligibility
for treatment with anti-VEGF therapy—either with TKIs
(eg, sorafenib) or monoclonal antibodies (eg, bevacizumab)—will also inform a treatment plan. Liver-specific
factors that need to be considered include the stage of
the HCC and the indication for treatment, the underlying synthetic liver function, and disease etiology and
its bearing—if any—on outcome. There are also certain
specific situations such as recurrence in the setting of
liver transplant that need further study, as well as the role
of biomarkers in predicting efficacy or toxicity. For many
of these considerations, the data are varied in terms of the
weight of evidence, which should be taken into account
in regard to the degree to which they should influence
the physician’s decision.
General considerations
Clinical trials demonstrating efficacy for immunotherapy
have largely been performed in patient populations
who were required to have a good performance status
(ie, Eastern Cooperative Oncology Group (ECOG) 0
to 1) in order to take part. This, of course, is a general
and widely accepted principle of oncology trials which
also applies to immunotherapy treatment, although
analyses have demonstrated no significant
two meta-
differences in OS between patients stratified by performance status between the groups with ECOG 0 and with
ECOG 1–2.109 110 The efficacy and tolerability of immunotherapy in patients with a performance status of >2 is
largely unknown. Another population that is frequently
excluded from trials and sometimes undertreated due
to concerns about frailty is the elderly. Subgroup analyses from IMbrave150, however, found that the safety
of atezolizumab in combination with bevacizumab was
largely identical between elderly (aged ≥65 years) and
non-elderly (aged <65 years) patients. Furthermore, clinical benefit with atezolizumab in combination with bevacizumab compared with sorafenib was confirmed, with
elderly patients having similarly improved OS, PFS, and
ORR as non-elderly patients.111
Cardiovascular toxicity risk is a major consideration
if anti-VEGF therapy is being considered as part of the
treatment plan for a patient with HCC. Anti-VEGF therapies are associated with increased bleeding risk, which
is an important consideration in this patient population,
many of whom will have portal hypertension. Awareness
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(CIKs), which are characterized by coexpression of CD3
and CD56 and can be generated by expanding human
peripheral blood mononuclear cells in the presence of
interferon-gamma (IFNγ).102 103 One randomized phase
III trial of CIKs as adjuvant therapy for patients with
HCC undergoing resection demonstrated a median
recurrence-free survival (RFS) of 44 months in the cell
therapy group and 30 months in the control group (HR
0.63; 95% CI 0.43 to 0.94; p=0.010 by one-sided log-rank
test).104 A meta-analysis of 13 phase II and phase III trials
involving CIKs for HCC that included a total of 1,212
patients found that cellular therapy was associated with
a significantly improved 1-year survival (OR 0.25; 95% CI
0.12 to 0.52; p<0.001) and 2-
year survival (OR 0.17;
95% CI 0.07 to 0.43; p<0.001), as well as a favorable DCR
(OR 0.09; 95% CI 0.04 to 0.25; p<0.001) and ORR (OR
0.21; 95% CI 0.13 to 0.35; p<0.001).105
Allogenic natural killer (NK) cell-based adoptive therapies have also been evaluated in HCC. One study that
included 40 patients with stage IV HCC found that NK
cell therapy synergized with irreversible electroporation
(IRE), leading to decreased AFP expression and higher
median OS compared with IRE alone (10.1 months vs
8.9 months; p=0.0078).106 Allogenic NK cell therapy also
showed synergy with cryoablation in a study that included
61 patients with advanced HCC. After a median follow-up
of 8.7 months (range 3.9–15.1 months), median PFS and
DCR were higher among the 35 patients who received
cryoablation plus NK cells compared with the 26 patients
treated with cryoablation alone (PFS 9.1 months vs 7.6
months; p=0.0107; DCR 85.7% vs 69.2%; p<0.01).107
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HCC-specific considerations
At present, the data in support of immunotherapy for
HCC apply to patient populations who are not amenable
to curative approaches for early-
stage disease such as
resection, ablation, transplantation, or locoregional
approaches for intermediate-stage disease (see Immunotherapies in development for HCC section for a discussion
of integration of immunotherapy with these approaches).
While immunotherapy for HCC in the neoadjuvant
setting cannot be recommended at this time, studies are
ongoing that will evaluate the safety and feasibility of
immunotherapy in the neoadjuvant or postoperative/
ablation setting. Encouraging results were reported in
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the final analysis of a phase II study evaluating nivolumab
alone or nivolumab with ipilimumab as neoadjuvant
therapy with an overall pathologic CR rate of 24% among
21 evaluable patients (2 patients in the nivolumab monotherapy group and 3 in the nivolumab plus ipilimumab
group). Grade 3 toxicity was experienced by five patients
receiving nivolumab plus ipilimumab and one receiving
nivolumab monotherapy, and no grade ≥4 toxicity was
HCC trial will also
reported.125 The phase Ib PRIME-
assess safety and bioactivity of preresection nivolumab
with ipilimumab in patients with HCC.126 Additionally, the
combination of neoadjuvant nivolumab and cabozatinib
has been evaluated in an open-label, single-arm, phase
I study in patients with borderline resectable or locally
advanced HCC. Among the 12 patients who underwent
successful surgical resection, 41.7% (n=5) had a major or
complete pathologic response with 80% of the pathologic
responders (n=4) remaining recurrence-free at a median
follow-up of 1 year. Resection specimens from patients
with responsive disease showed evidence for enrichment
of IFNγ+ effector memory CD4+ T cells as well as granzyme
B+ effector CD8+ T cells.127
HBV infection is the etiological agent for as much as
50% of the incidence of HCC worldwide,128 and HCV
is estimated to account for up to one-third of cases.129
HCV-associated advanced HCC was the first setting in
which ICIs were evaluated, although modest response
rates and a median time to progression of 6.4 months
were observed in the initial study’s 21-
patient cohort
treated with tremelimumab.69 Adequate viral control
was reported in hepatitis-infected, ICI-treated patients in
CheckMate 040 and KEYNOTE-224, and no worsening
of hepatitis was observed.13 14 Published trials, however,
required patients with HBV infections to be on antiviral
therapy. Another retrospective study of outcomes among
immunotherapy-treated patients with concomitant HBV
or HCV infections (among which HCC was the most
common tumor type) found no evidence for viral reactivation and similar incidences of grade ≥3 irAEs, as well as
ORRs compared with those observed in registration trials
of approved anti-PD-1 therapy.130 However, the immune
landscape of HBV-associated HCC is generally thought
to be profoundly suppressed and exhausted, which could
potentially alter the efficacy of ICI therapy. A pooled
analysis of anti-PD-(L)1 therapy trials for HCC found that
although HBV-positive patients achieved ORRs comparable to those of HBV-negative patients (OR 0.68; 95% CI
0.37 to 1.25; p=0.21), the DCRs were significantly lower
for HBV-positive patients compared with HBV-negative
patients (OR 0.49; 95% CI 0.27 to 0.89; p=0.02).131
A recent meta-analysis by Pfister et al132 found differential survival outcomes depending on HCC etiology in 1,656
patients in randomized trials of ICIs as monotherapy or
in combination with bevacizumab. In the analysis, checkpoint blockade was not associated with improved survival
in patients with non-viral HCC, in marked contrast to the
overall cohort and patients with viral etiology. In addition, survival was also diminished in two smaller cohorts
11
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of contraindications to anti-VEGF therapy is important,
particularly as these agents become further incorporated
into evolving immune-based standards of care. A recent
analysis found that as many as 35% of patients with cancer
receiving bevacizumab were treated despite the presence
of contraindicating comorbidities.112
HCC is often diagnosed at an advanced stage in patients
living with HIV, and the hepatotoxicity of highly active
antiretroviral drugs may further exacerbate underlying
liver damage.113 114 Historically, patients with HIV have
been excluded from trials, leading to an unmet need
for effective therapies in this population—a group that
also has poorer outcomes in HCC, specifically, compared
with HIV-negative individuals.115 Although not yet studied
specifically in HCC, tolerable safety and efficacy with ICI
therapy for a variety of solid tumors has been demonstrated for patients living with HIV.116 117
Patients with a history of autoimmune disorders have
also historically been excluded from immunotherapy
clinical trials given the mechanisms of action of immunotherapy agents and the risk of exacerbating existing
autoimmunity. At present, the evidence for safety of ICIs
in patients with pre-existing autoimmunity is limited to
retrospective studies and case reports,118 which likely are
not generalizable. Although one meta-analysis found that
flares and irAEs in patients with autoimmune diseases
treated with ICIs could often be managed, some events
were severe and fatal. The overall incidence, however,
could not be determined due to a lack of prospective
studies.119 In addition, several studies have shown worse
outcomes after ICI therapy among patients who were
already taking steroids or immunosuppressive medication at baseline.120 121
Finally, racial and ethnic minorities have been reported
to have higher rates of mortality from HCC in the USA.122
Minority groups also have a history of underrepresentation in clinical trials,123 meaning that often these patients
not only often lack access to the best care for their disease
but also that clinicians must extrapolate from data on
the majority population for decision-making due to lack
of direct evidence for efficacy.124 Awareness of historical
disparities and efforts to include diverse populations in
future studies is important to improve outcomes for all
patients.
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Biomarkers for ICI efficacy and safety in HCC
ICIs provide benefit for only a subset of patients. The
ability to identify intrinsic resistance to ICIs would allow
patients to attempt other therapies, which could, most
importantly, lead to better outcomes, while also saving
12

healthcare resources. Unfortunately, validated blood or
tissue biomarkers for ICI resistance are currently lacking
in the clinical setting. Early studies have also returned
conflicting results. High serum AFP levels are associated with increased sensitivity to the anti-VEGF receptor
(VEGFR) monoclonal antibody ramucirumab.136 Post
hoc subgroup analysis of randomized trials have shown
that the HR for OS was slightly lower among patients with
high AFP in KEYNOTE-240 (pembrolizumab vs placebo)65
and CheckMate 459 (nivolumab vs sorafenib),137 while
the contrary was observed in IMbrave150 (atezolizumab
with bevacizumab vs placebo).16 69 Furthermore, objective remissions occur irrespective of AFP levels after
nivolumab or pembrolizumab monotherapies, or the
combination of ipilimumab and nivolumab.
A number of features of the tumor microenvironment
have been associated with HCC prognosis, including
overall lymphocyte infiltration, density of Tregs, and
tumor-
associated macrophages (TAMs), especially if
M2-
polarized. In melanoma, the presence of conventional type 1 dendritic cells seems critical to promote a
T and NK cell infiltrate and for the action of ICIs.138 In
HCC animal models, β-catenin-mutations in HCC (which
are present in around 25% of human HCCs) result in
a paucity of intratumoral conventional type 1 dendritic
cells,139 and it has been proposed that β-catenin defects
may be used to identify patients with disease that will
fail to respond to PD-1 blockade.140 This feature awaits
investigation in clinical trials. Soluble factors also modulate the immune response against HCC. For example,
transforming growth factor beta (TGF-β) downregulates
antitumor responses through a variety of different mechanisms, and high levels of the cytokine shape the response
to pembrolizumab.141
Pretreatment tumor infiltration by T cells and their
activity status are key to determine response to ICIs in
various cancers. In advanced HCC, CD4+ and CD8+ T cell
infiltration showed weak correlations with survival after
second-
line treatment with PD-1 inhibitors in CheckMate 040.142 In the trial, deep antitumor responses were
observed regardless of PD-L1 expression after nivolumab
treatment, although the response rate was higher among
patients with at least 1% of tumor cells expressing
PD-L1.142
On the other hand, PD-
L1 expression in tumor or
stromal immune cells was higher among responders to
pembrolizumab, but remissions also occurred in the
absence of expression in both cell types.65 In CheckMate
459, median OS after nivolumab and sorafenib was 16.1
months versus 8.6 months among patients that had tumor
PD-L1 expression ≥1% (HR 0.80), and 16.7 months versus
15.2 months among those that had tumor PD-L1 expression <1% (HR 0.84).137 Interestingly, macrophage infiltration, including M2-polarized TAMs, was not associated
with clinical outcomes after nivolumab treatment. A meta-
analysis including 894 patients across nine trials of ICIs
in advanced HCC found a positive association between
PD-L1 expression and response to therapy—especially for
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of patients with HCC and documented NAFLD. Although
provocative and interesting, future prospective confirmatory studies are needed to understand if and how etiology
affects the liver immune microenvironment. Of note, a
separate study that did not include patients treated in
IMbrave150 found no differences in ORRs nor features
of the tumor microenvironment (TME) that are known
to modulate responses to ICIs between patients with viral
and non-viral HCC.133
Relatively few trials have included patients with Child-
Pugh B cirrhosis, a population for which few treatment
options are available. In a retrospective case series of 18
patients with Child-Pugh B cirrhosis and advanced HCC
who were treated with nivolumab, 94% (17 of 18) experienced a grade ≥3 AE, with treatment-related grade ≥3
AEs reported in 28% (5 of 18). IrAEs were reported in
50% of patients (9 of 18), and 28% (5 of 18) required
steroids. Treatment-
related AEs led to discontinuation
of therapy in four patients (22%).59 In the Child-Pugh
B cohort of CheckMate 040, 49 patients with Child-Pugh
B7 to B8 advanced HCC who were sorafenib-naïve (n=25)
or sorafenib-
experienced (n=24) received nivolumab
monotherapy. Investigator-assessed ORR was 12% (95%
CI 5% to 25%) and the DCR was 55% (95% CI 40% to
69%). Safety was similar to that seen with nivolumab in
patients with Child-Pugh A disease. At a median follow-up
of 16.3 months, median OS was 7.6 months for the entire
cohort—median OS in sorafenib-
naïve and sorafenib-
treated patients were 9.8 and 7.4 months, respectively.61
Importantly, there is no evidence to date indicating that
immunotherapy causes further damage to impaired livers.
Patients with tumor invasion of the main trunk of the
portal vein, invasion of the portal vein branch contralateral to the primarily involved lobe (Vp4), bile duct
invasion, and/or tumor occupying ≥50% of the liver are
considered high risk. Data from IMbrave150 indicates
that atezolizumab with bevacizumab is safe and effective
in patients with high-risk features. Although more grade 5
upper gastrointestinal hemorrhage events were reported
in high-risk patients receiving atezolizumab with bevacizumab, none of these grade 5 events were considered by
investigators to be related to treatment.134 However, variceal bleeding is a potential toxicity of anti-VEGF agents.
Therefore, for patients treated with atezolizumab in
combination with bevacizumab, esophagogastroduodenoscopy to evaluate for varices within 6 months of initiating therapy is recommended.135
Finally, patients who have received liver transplants are
typically excluded from clinical trials due to concerns
about graft rejection, and high rates of rejection and
mortality have been reported in the limited cases
published thus far.87
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(PLR) have shown a strong prognostic impact in HCC
across tumor stages. Lower NLR has been associated
with better outcomes after sorafenib,157 158 and similar
trends are emerging from trials of ICIs. In CheckMate
040, patients progressing on nivolumab had a higher
NLR and PLR than patients who had disease control as
the best overall response.142 Consistent with this observation, a retrospective analysis of 103 patients who received
nivolumab found that patients with Child-Pugh A disease
who achieved PR or CR had significantly lower post-
treatment NLR and PLR (p<0.001 for both) compared
with patients who had stable or progressive disease.159
The composition of the gut microbiota, which has
been linked to the promotion of HCC development and
progression through secreted metabolites,160 161 may also
predict response to treatment, although current analyses in the liver cancer setting are small and preliminary.
Gut microbial diversity has been linked to ICI efficacy in
epithelial tumors,162 and retrospective analysis has shown
that antibiotic use is associated with worse outcomes with
immunotherapy in lung and renal cancer,163 a finding that
has also been replicated in a prospective trial including
several additional tumor types.164 One pilot study of eight
patients with HCC treated with anti-PD-1 therapy after
progression on sorafenib found that patients with responsive disease displayed higher taxa richness and more
gene counts in their microbiota compared with non-
responders, with enrichment for 20 distinct species of
bacteria, including Akkermansia muciniphila and the Ruminococcaceae family.165 The potential for the gut microbiota
to shape responses to immunotherapy is an ongoing area
of research, but, at present, the state of the data is not
sufficient to alter management in this regard and clinical
judgment outweighs other considerations.
An additional ongoing area of research is the identification of biomarkers for the prediction of which patients
will experience irAEs with ICI therapy. Several studies
have reported a link between various clinical and blood-
based or serological factors and the onset of immune-
related toxicity, although none have been prospectively
validated for HCC. Patients with sarcopenia166 167 and of
female sex168 169 have both been shown to have higher
incidences of irAEs. Additionally, the composition of
the gut microbiota may play a role in predicting which
patients will develop ICI-associated colitis.170 Additional
factors under active investigation for prediction of toxicity
include elevated cytokine levels at baseline, such as interleukin (IL)-6169 and IL-17,171 as well as the presence of
autoantibodies.172 173 Currently there are no clinically validated biomarkers to predict the risk of irAEs.
Recognition and management of irAEs
The same mechanisms by which immunotherapy drugs
exert their therapeutic effects also underlie their unique
toxicities—suppression of the inhibitory mechanisms that
protect tissues from uncontrolled immune responses.
Unlike AEs with chemotherapy or other treatment modalities, irAEs may be delayed in onset and have prolonged
13
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single-agent anti-PD-1. Strikingly, in the analysis, PD-L1
expression status had minimal association with response
to therapy for patients being treated with anti-CTLA-4-
containing combinations.143 Analytical heterogeneity
in PD-
L1 expression is substantial, however, and may
contribute to the performance of this test as a predictive
biomarker.144
Several inflammatory gene signatures are correlated
with higher response rate and improved OS after
nivolumab treatment.142 Interestingly, the most complex
transcriptomic classifications of inflammatory HCC
including a large number of genes145 were not identified
as predictive of response in this analysis, suggesting that
short gene signatures may be more relevant for clinical
development. Regarding ICI combinations, objective
remissions occurred with ipilimumab plus nivolumab
irrespective of PD-
L1 expression in tumor cells.146 An
early burst of Ki67+CD8+ cells in the peripheral blood
was also seen in one of the randomized expansion
cohorts for Study 22, which evaluated combinations of
durvalumab and tremilimumab at different dosing regimens,74 hinting that cytotoxic T cell proliferation after
therapy may predict response. Altogether, though, it
seems unlikely that a single biomarker could be used to
inform clinical decisions in a timely fashion. However,
it is probable that composed and integrative multifactorial indexes might help identify patient subsets who are
likely to benefit, further underscoring the importance of
obtaining pretreatment tumor biopsies for future translational studies.
Pembrolizumab is FDA-
approved for two tissue-
agnostic indications based on tumor-intrinsic characteristics. Approval for pembrolizumab for the treatment of
microsatellite-high (MSI-H) or mismatch repair deficient
(dMMR) tumors was based on a pooled ORR of 39.6%
(95% CI 31.7% to 47.9%), with a 7% CR rate among 149
patients with 15 different tumor types in five single-arm
multi-
cohort multicenter trials: KEYNOTE-016,147
KEYNOTE-164,148 KEYNOTE-012149 KEYNOTE-028,150
and KEYNOTE-158.151 Approval for pembrolizumab
for non-
MSI-
H/dMMR tumors with high mutation
burden (TMB-H)—defined as ≥10 mutations per megabase (mut/Mb) as assayed by the FoundationOne CDx
companion diagnostic—was based on KEYNOTE-158.152
No patients with HCC were included in the cohorts upon
which the tissue-agnostic indications for pembrolizumab
were approved, however.
TMB correlates with the number of neoantigens and
response to ICIs in tumors with >20 somatic mut/Mb,
such as melanoma.153 154 However, HCC is infrequently
MSI-
H/dMMR or TMB-
H. One study that performed
comprehensive genomic profiling of 755 patients with
advanced HCC found a median TMB of 4 mut/Mb and
that only six tumors (0.8%) were TMB-H. Furthermore,
out of 542 cases assessed, only one (0.2%) was MSI-H.155
Another analysis found a rate for MSI-H as low as 6%.156
Markers of systemic inflammation like neutrophil to
lymphocyte ratio (NLR) and platelet to lymphocyte ratio
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IrAEs specific to the treatment of HCC
Outside of immune-
mediated hepatotoxicity, the
commonly reported AEs in published trials leading
to ICI approvals for HCC have been generally comparable to those seen in other disease settings. Pembrolizumab monotherapy showed a tolerable safety profile
in KEYNOTE-224, with the most common irAEs of any
grade being hypothyroidism (n=8, 8%) and adrenal insufficiency (n=3, 3%).14 In the cohort of patients receiving
nivolumab monotherapy in CheckMate 040, the most
common AEs were pruritus (n=9, 11%) and rash (n=11,
23%).13 The addition of ipilimumab to nivolumab, as evaluated in cohort 4 of CheckMate 040, was associated with
a wider variety of toxicities with the most common AEs of
any grade being rash (n=14, 29%), pruritus (n=22, 45%),
diarrhea (n=12, 24%), decreased appetite (n=6, 12%),
fatigue (n=9, 18%), adrenal insufficiency (n=7, 14%), and
hypothyroidism (n=10, 20%).178 For the combination of
14

atezolizumab with bevacizumab in IMbrave150, the most
common adverse reactions were hypertension (n=98,
29.8%), fatigue (n=67, 20.4%), and proteinuria (n=66,
20.1%), and no serious AEs with a difference in incidence
of >2% were noted between the atezolizumab with bevacizumab and sorafenib treatment groups.16
Drug-induced hepatotoxicity
HCC usually develops in a background of chronic liver
disease, which itself may give rise to systemic manifestations. Cirrhosis is characterized by diffuse fibrosis of the
liver, altered hepatic blood flow and portal hypertension,
and progressive failure of liver functions. In parallel, other
organs frequently develop secondary dysfunction. Many
extrahepatic disorders associated with cirrhosis cause
symptoms that may mimic irAEs and therefore lead to
overdiagnosis or underdiagnosis of toxicities with immunotherapy. Late recognition of irAEs may delay treatment
and worsen the prognosis. Overdiagnosis may result in
inappropriate interruption of ICIs, complications caused
by immunosuppressive therapy, unnecessary diagnostic
procedures, and increased cost. Such disorders can also
synergize in causing deteriorating organ function when
irAEs occur. The most important cirrhosis-related disorders that may compromise the management of irAEs are
summarized in table 5.
Patients with HCC and underlying liver disease are at
high risk for decompensation with additional insult to
the organ. Some studies have found that underlying liver
disease as opposed to cancer progression is the ultimate
cause of death in almost half of patients with HCC.108
Elevated liver enzymes without clinical impairment in
hepatic function were commonly reported in all of the
trials that led to approvals of ICIs for HCC.13–15 Grade 3
or 4 elevations in liver enzymes were reported in 16% of
patients in the dose‐escalation arm of CheckMate 040 and
in 12% of the patients in KEYNOTE‐224.14 In KEYNOTE240, immune-mediated hepatitis events were seen in 10
patients (3.6%) in the pembrolizumab group, approximately 90% of which resolved.65
No prospective trials have defined the best treatment
approach for drug-
induced hepatotoxicity in patients
with HCC receiving immunotherapy. The package inserts
for pembrolizumab, nivolumab, and atezolizumab all
recommend monitoring for changes in liver function and
administering corticosteroids for hepatitis followed by a
taper. ICIs should also be withheld or discontinued if liver
enzymes or bilirubin become elevated, with the thresholds varying depending on baseline values and the drug
regimen being given.179 Exclusion of other causes of acute
liver damage—including toxicities from concomitant
medications, use of herbal supplements, viral hepatitis,
and particularly tumor progression—is key to adequate
management.
Response evaluation
Measurement of response rate in HCC has been controversial. The WHO (WHO) criteria180 and the RECIST
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duration, sometimes months or years after initial exposure to therapy. The overall incidence and severity of
irAEs reported in phase III trials of anti-PD-(L)1 agents
varies depending on disease state and comorbidities.
Most irAEs are of mild-
to-
moderate severity, but life-
threatening events have been reported. A meta-analysis
of fatal ICI-associated toxicities encompassing more than
16,000,000 adverse drug reactions from the medical
records from the VigiBase-
VigiLyze database found a
total of 613 deaths related to ICIs. The fatalities related to
anti-CTLA-4 therapy were most often from colitis (n=135,
70%), while fatalities associated with anti-PD-(L)1 were
most often from pneumonitis (n=333, 35%), hepatitis
(n=115, 22%), and neurotoxic effects (n=50, 15%).174
A systematic review including 48 clinical trials involving
7,936 patients treated with nivolumab monotherapy or
combination nivolumab and ipilimumab found that the
double regimen was associated with more all-grade and
grade ≥3 irAEs categorized by system, organ, or class
(p<0.05). Additionally, the ORR of nivolumab combined
with ipilimumab was positively correlated with the incidence rate of skin (r=0.54; p=0.04) and gastrointestinal
irAEs (r=0.60; p=0.02), but not endocrine, hepatic,
pulmonary, or renal irAEs.175 Similarly a recent observational study including 331 patients with HCC receiving
anti-PD-(L)1 monotherapy or combinations found that
the emergence of treatment-related AEs of grade ≥2 while
on ICI therapy predicted for improved OS (median 19.7
vs 11.0 months; HR 0.32; 95% CI 0.16 to 0.65; p=0.001)
and increased ORR (30% vs 16%; χ2 5.9; p=0.01).176
Typically, the management of irAEs includes interruption of ICIs, corticosteroids, and occasionally the
administration of immunomodulatory agents including
tumor necrosis factor (TNF) inhibitors. Detailed recommendations on the recognition and management of
ICI-
associated AEs have been published elsewhere177
and the general principles contained therein may guide
treatment decisions for irAEs, which are not specific to
patients with HCC.
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Organ

irAE

Chronic liver disease

Skin

►► Pruritus
►► Rash
►► Erythema multiforme,

►► Pruritus
►► Skin disorders, including lichen planus, polyarteritis nodosa,

Liver

►► Hepatitis

►► Flares or viral infection

Lung

►► Pneumonitis

►► Hepatopulmonary syndrome
►► Porto-pulmonary hypertension

Thyroid

►► Hypothyroidism
►► Hyperthyroidism
►► Graves’ disease

►► Reduced peripheral conversion of T4 to T3
►► Thyroid dysfunction

Adrenal glands
and pituitary
glands

►► Adrenal insufficiency
►► Hypophysitis

►► Hypogonadism
►► Hypothalamic-pituitary dysfunction
►► Relative adrenal insufficiency

Kidney

►► Nephritis

►► Hepatorenal syndrome
►► Mixed cryoglobulinemia (HCV-related)
►► HBV-related nephropathy
►► IgA nephropathy

Nervous system

►► Encephalitis
►► Aseptic meningitis
►► Peripheral neuropathy
►► Myasthenia gravis
►► Guillain-Barre syndrome
►► Autonomic neuropathy
►► Transverse myelitis

►► Porto-systemic encephalopathy (typical and atypical)
►► Viral-related peripheral neuropathy
►► Wernicke’s encephalopathy
►► Autonomic neuropathy (HCV-related)

Blood and bone
marrow

►► Cytopenias
►► Hemolytic anemia
►► Red cell aplasia
►► Bone marrow failure
►► Hemophilia A
►► Hemophagocytic

►► Hypersplenism and bone marrow depression
►► Anemia due to folate or iron deficiency
►► Hemolytic anemia
►► Viral-related thrombotic thrombocytopenic purpura and aplastic anemia
►► Immune thrombocytopenia (HCV-related)
►► Lymphopenia related to HCC therapies

GI tract

cryoglobulinemic vasculitis, and porphyria cutanea tarda (HCV- and
HBV-related)
psoriasis, urticaria and
rosácea
►► Severe cutaneous adverse
reactions
►► Diarrhea
►► Small intestine bacterial overgrowth
►► Colitis
►► Chronic pancreatitis

lymphohistiocytosis

►► Macrophage activation

syndrome

GI, gastrointestinal; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; irAE, immune-related adverse event.

guidelines181 define standard measurement methods for
converting radiology image observations into quantitative and statistically tractable frameworks for measuring
changes in tumor size associated with therapy. However,
assessments based solely on tumor size are misleading
when applied to molecular targeted therapies and immunotherapies. For HCC in particular, poor correlation has
been shown between the clinical benefits provided by
sorafenib or locoregional interventional therapies and
RECIST-based responses.182 Subsequently, the concept
of ‘viable tumor’ was endorsed by the guidelines for the
design of HCC clinical trials developed by AASLD183
and eventually incorporated into a formal proposal to
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794

amend standard RECIST criteria to address the unique
complexity of HCC response assessment. The amended
criteria were named mRECIST for HCC.184 In published
trials of immunotherapy for HCC, RECIST v1.1 was used.
In the immunotherapy setting, no significant differences
exist between RECIST and mRECIST.
Several clinical investigations have shown that objective response measured by mRECIST predicts survival in
patients treated by locoregional therapies. A meta-analysis
including seven trials and 1,357 patients reported an OS
HR (responders vs non-responders) of 0.39 (95% CI 0.26
to 0.61; p<0.0001).185 Another study found that EASL
and mRECIST both outperformed the WHO criteria and
15
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Table 5 Cirrhosis-related disorders that should be considered in the diagnostic workup of irAEs in patients with HCC
(Adapted from Sangro et al, J Hepatol 2020)179
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Panel recommendations
For patients with advanced-
stage HCC and for
patients with earlier-stage disease where liver-directed
therapies are not considered appropriate or who
have progressed after liver-directed therapy, the data
at present supports first-line and subsequent-line ICI
therapy use (LE: 2). Further studies are needed to
confirm the efficacy of immunotherapy in the curative setting (neoadjuvant/adjuvant/perioperative) or
in conjunction with intra-arterial therapies.
►► In patients with HCC with cirrhosis, the data supports
the use of immunotherapy in patients with underlying synthetic liver function consistent with well-
compensated cirrhosis, specifically Child-Pugh A (LE:
2). The panel recognizes, however, that some carefully selected patients with Child-Pugh B may derive
benefit (LE: 3).
►► Patients who have contraindications for the use of
TKIs or anti-
VEGF therapies (eg, cardiovascular
comorbidities) may be suitable for anti-PD-1 monotherapy (LE: 1).
►► The panel recommends against the use of immunotherapy in the post-transplant setting (LE: 4) due to
the high risk of graft failure, given known mechanisms of ICIs.
►► Additional studies are needed to assess the potential
risks and benefits of immunotherapy in the pretransplant setting.
►► The panel agrees that patients can be considered for
immunotherapy treatment irrespective of hepatitis
viral etiology (LE: 3), though it is strongly recommended that patients with HBV be on concomitant
antiviral medication and adherent.

►►

►►

►►

►►

►►

►►

►►
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►►

►►
►►

►►

While patients living with HIV have not been included
in clinical trials to date, the panel believes that this
is not an absolute contraindication to treatment
with immunotherapy as long as the appropriate HIV
therapy is instituted as per expert guidance (LE: 2),
while further dedicated studies to assess such therapies in patients living with HIV remain critical.
Historical disparities in access to clinical trial participation for underrepresented groups should be
considered, with efforts made to support diversity,
equity, and inclusion.
The panel recommends against the use of routine
testing of biomarkers for predicting immunotherapy
efficacy, which, at this point, remains exploratory.
The panel recommends against the use of routine
testing of biomarkers for predicting irAEs, which, at
this point, remains exploratory.
Response assessment can be performed according to
mRECIST criteria in patients receiving locoregional
interventional therapies (LE: 3).
Limited data are available concerning the value of
mRECIST and immune-related RECIST (irRECIST)
criteria in the setting of HCC response assessment,
especially in the context of ICI therapy. Further
studies are needed to compare outcomes between
patients with response to treatment by mRECIST
versus irRECIST.
Pseudoprogression, while a real phenomenon, occurs
rarely (LE: 4). A comprehensive assessment is encouraged. In published trials, treatment beyond progression has been allowed.
Hyperprogression may occur (LE: 4). It is uncommon,
cannot be anticipated, and remains poorly understood.
Caution should be exercised in translating response
assessment models developed for clinical trials into
clinical practice.
For management of irAEs in patients with HCC, refer
to general principles in published guidelines.

PATIENT SUPPORT AND QOL
Immunotherapies and targeted therapies have extended
survival for patients with HCC, but these new agents are
not curative in most cases, and their unique toxicities can
affect QOL. The importance of QOL as an independent
prognostic factor for response to treatment or predicting
disease progression is becoming more appreciated—
several studies have demonstrated associations between
baseline patient-reported QOL and survival in HCC.195–197
Therefore, immunotherapy treatment plans should take
patient QOL at baseline and on therapy into account.
Additionally, it is important for clinicians to provide
patients with necessary and sufficient information to
help them navigate treatment without undue emotional
or financial distress. Referral to support groups is also
highly encouraged, including the American Liver Foundation, Blue Faery: The Adrienne Wilson Liver Cancer
Association, Cancer Support Community, the Fatty Liver
Foundation, and the Global Liver Institute. In addition,
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RECIST for patients undergoing DEB-TACE.186 Recently,
data from randomized trials confirmed that objective
response by mRECIST predicts survival in patients with
advanced-
stage HCC receiving systemic therapies with
TKIs, and suggested that objective response by mRECIST
can be considered as a candidate surrogate end point of
OS, although further research is needed to support this
finding.187 188
Although late response after apparent disease progression on imaging has been reported in the context of
immunotherapy for HCC,189 the overall incidence of
pseudoprogression with ICI treatment is rare. Estimated
rates of psuedoprogression across published studies range
from 2%–10%.190 191 Also rare, though possible, is a rapid
acceleration in tumor growth after anti-PD-(L)1 therapy,
a phenomenon called hyperprogression.191 192 Although
published evidence is limited, hyperprogression has been
reported in small case series of patients with HCC treated
with ICIs,193 and retrospective analyses.194 Importantly,
the evidence to date has only reported hyperprogression
in the setting of anti-PD-(L)1 monotherapy—it is unclear
whether the addition of VEGF-directed antibodies to ICI
therapy affects the likelihood of hyperprogressive disease
after treatment.
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Patient and caregiver education
Prior to diagnosis, the majority of patients and their caregivers will likely be unfamiliar with HCC, and they may
harbor misconceptions about the etiology of the disease,
potentially leading to stigma and shame over and above
the emotional distress associated with a cancer diagnosis.198 Among different types of cancer, HCC has been
found to rank third highest in terms of levels of emotional
distress experienced by patients.199 Rehabilitation, palliative care, and psycho-oncology have been insufficiently
studied in liver cancer.
Perceived stigma surrounding liver disease may cause
patients to delay care or avoid seeking social support,
which negatively impacts QOL.200 The majority of HCC
cases worldwide are secondary to HBV or HCV infection,4
with NASH increasingly becoming the primary cause in
the US and Europe.5 However, a survey of HCC caregivers in the US found that 72% were under the mistaken
impression that heavy alcohol use was the most common
risk factor for liver cancer.201 Stigma surrounding HBV
may be more pronounced in certain populations, such as
people of Asian descent,202 203 so it is important for healthcare providers to be sensitive and culturally informed in
their communications with patients.
HCC is a disease within a disease, and patients as well as
their caregivers need to understand that their treatment
journey will involve both the cancer itself as well as underlying liver damage. Patients with HCC often receive care
from a multidisciplinary team that may include oncologists, hepatologists, surgeons, gastroenterologists, endocrinologists, and other specialists. In addition to the care
team responsible for administering therapy targeting the
tumor and the liver, patients will need ‘whole-person’
support for psychosocial and spiritual concerns, especially
during end-of-life care.204 205 Depending on the stage of
their disease (for more details on staging systems for HCC,
see the Diagnostics and staging for patients with HCC
section), a patient may be receiving information from a
large number of different providers, especially in cases
of intermediate-stage HCC.205 Additionally, practitioners
from other specialties may have limited knowledge about
the unique mechanisms of action of immunotherapies,
and the accompanying potential for toxicities, making
ongoing communication between a patient and their
treating oncologist paramount.
Currently, immunotherapy is only approved for patients
with advanced disease. Patients may be unfamiliar with
the stages of liver cancer and the difference between
treatments with curative intent and palliative therapy.
Further complicating matters, patients may have preconceived notions shaped by media portrayals of high-profile
immunotherapy success stories, while being less knowledgeable about the realistic efficacy and potential toxicities with treatment.206 Early referral to palliative care has
been shown to improve QOL in patients with non-small
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cell lung cancer,207 yet palliative care is underutilized in
patients with end-stage liver disease.208 209 Patients with
cirrhosis who are ineligible for transplant are also underserved with appropriate palliative care.210 It is important
for patients to understand that immunotherapy for HCC,
even if it may extend OS, is a palliative treatment used in
advanced stages of the disease and not curative in intent,
so that they may be referred to advanced care planning
early on in their treatment.
Considerations for administration, dosing and monitoring
The tolerability of immunotherapy is, for the most part,
better than conventional cancer treatments, although
future combination strategies (eg, ICIs with TKIs) may
be associated with less favorable toxicity profiles.211 The
administration, dosing, and monitoring considerations
for immunotherapy may be distinct from what a patient
or caregiver is expecting based on experience with prior
therapies or conversations with other healthcare providers
who do not specialize in immunotherapy. Therefore, it is
important to discuss the potential for irAEs and the signs
and symptoms of expected toxicities with patients and
caregivers. Additionally, patients must understand how
liver comorbidities may affect the efficacy of immunotherapy for HCC (see the Patient selection and management section for considerations for healthcare providers).
It is important for patients and caregivers to have clear
and detailed instructions for when to contact their healthcare providers due to symptoms of irAEs, and examples of
call parameters are provided in box 1.
Box 1 Patient and caregiver education for call
parameters for irAEs
You should contact your healthcare providers for any of the following
symptoms (or call 911 or seek emergency services as indicated)*:
►► Abdominal pain
►► Change in stool (blood or mucus in stool, change in color, light or
clay colored)
►► Increase in bowel movements, >3 movements above a patient’s
baseline
►► Diarrhea, >3 watery stools
►► Nausea or vomiting
►► Jaundice (yellowish skin color)
►► Difficulty breathing, shortness of breath, or chest tightness
►► New non-productive dry cough
►► Mental status changes
►► New visual disturbances
►► Headache
►► New or worsening fatigue
o
►► Fever with temperature >100.4 F (38°C)
►► New weakness, muscle or joint pains
►► Unintentional weight loss >3 lbs (1.5 kg)
►► Significant weight gain with obvious abdominal swelling
►► Rash which may or may not be accompanied by tenderness or
itching
*Note to providers: Call parameters for patients highlight the following
conditions: colitis, pneumonitis, endocrinopathies, dermatologic toxicities. It
should be noted that many conditions have overlapping symptoms.
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information provided by the National Cancer Institute
and SITC may be helpful for patients.

Open access

Special considerations for patients with HCC
Patients with HCC have been found to have lower health-
related QOL (HRQOL) than the general population,
especially for measures of physical, psychological, and
functional well-
being, as well as hepatobiliary symptoms.219 Both physical and psychological factors may influence a patient’s QOL, and a person’s self-perception and
coping mechanisms may modulate their status. In patient
interviews, HCC has been found to be perceived as a long-
term and chronic disease that cannot be cured but might
be controlled, and coping strategies can include focusing
as much as possible on managing HCC and its symptoms,
emotional responses, and leading a normal life.221 Those
mental constructs can affect feelings about physical
symptoms, and it has been demonstrated that patients
with negative illness perceptions who use more emotion-
oriented coping had worse HRQOL.222 However, rigorous
studies on interventions targeting disease perception or
coping mechanisms are currently lacking.
Pain, particularly upper quadrant abdominal pain,
is common in patients with HCC.223 Pain management
may be difficult because approximately 80% of patients
with HCC have cirrhosis,224 and liver damage can alter
drug pharmacokinetics. Perhaps due to confusion about
efficacy and safety for opioid and non-opioid analgesics,
patients with HCC are undertreated for pain.225 However,
some generally safe options for pain management for
patients with impaired liver function exist, including
opioids, non-steroidal anti-inflammatory drugs (NSAIDs)
in some cases, topical lidocaine patches (which have low
levels of systemic absorption) for localized analgesia,
18

tricyclic antidepressants, and anticonvulsants such as
gabapentin (which is not metabolized by the liver).226
Financial toxicity is a major concern for patients with
cancer,227 and immunotherapies are among the most
expensive agents on the pharmaceutical market.228 229
Patients with cancer shoulder the burden of an increasing
number of out-of-pocket costs for their treatment, even
if they have insurance coverage.230 Treatment may cause
both material and psychological financial hardship, and
the risk factors for each vary. Patients of younger age,
female sex, non-white race, and who change employment
because of cancer are more likely to experience material financial hardship, whereas psychological hardship
is more likely among those who are uninsured or have
lower family income.231 The degree to which cancer
causes financial burden has been shown to be the single
most important predictor for poor QOL,232 and healthcare costs for HCC are substantial. In both North America
and Asia, costs are highest for patients with HCC in the
terminal phase of care.233 Although a comprehensive
analysis of the healthcare costs associated with immunotherapy in the HCC setting has not yet been performed,
oncologists should communicate with patients about how
treatment may affect their financial well-being, as health
insurance may not cover the costs of immunotherapy
drugs.
Importantly, however, immunotherapy has generally
been associated with favorable QOL outcomes compared
with previous standards of care. In the landmark trials
leading to FDA approval of checkpoint inhibitors for
HCC, no adverse effects on QOL were observed when
outcomes were reported for the patients receiving immunotherapy. Nivolumab was associated with stable patient-
reported outcomes, including indicators of health status
and QOL regardless of prior sorafenib in CheckMate
040.13 It is noteworthy to mention that even in a subcohort
of patients from the CheckMate 040 trial with impaired
liver function (Child-Pugh B), the AE profile was comparable to what was seen in patients with Child-Pugh A
disease.59 Additionally, IMbrave150 provided a large and
rich data set on patient-reported QOL outcomes, which
complemented the efficacy data, with a reporting rate of
greater than 90%. The study found that fewer patients
treated with the combination of atezolizumab with bevacizumab experienced QOL deterioration compared with
those receiving sorafenib. Furthermore, for the patients
who did experience QOL deterioration on immunotherapy, the onset was later.234 Pembrolizumab also was
shown to preserve HRQOL in a prespecified exploratory
analysis of patients enrolled in KEYNOTE-240. Among
the 271 and 127 patients randomly assigned to pembrolizumab and placebo, respectively, who completed the
EORTC QLQ-
C30 and the HCC supplement EORTC
QLQ-HCC18, changes in both scores were similar across
arms and global health status/QOL scores were stable.235
It will be important to prospectively study QOL outcomes
in future immunotherapy trials, especially as new combination regimens advance through clinical development.
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794
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The ICIs that are currently approved for HCC are typically given as IV infusions, whereas TKIs such as sorafenib
are oral medications. Because immunotherapy is usually
administered at an infusion center, access to care may be
a challenge for some patients, especially those in rural
areas.212 213 However, a potential benefit of the requirement for inperson infusions is the opportunity for contact
with a treating physician if AEs do occur. Additionally,
although patients receiving palliative chemotherapy have
been found to prefer oral administration over IV, the
majority are not willing to accept a decreased response
rate or shorter DOR,214 which is likely also true when
deciding between IV immunotherapy versus other oral
medications.
Multiple liver-
specific assessment instruments have
been developed to monitor QOL in patients with HCC,
including the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire
Core-18 (EORTC QLQ-HCC18),215 the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep),216
the FACT Hepatobiliary Symptom Index (FHSI),217 and
the QOL-liver cancer (QOL-LC).218 However, multiple
systematic reviews have found that the most used assessment tool is the EORTC Quality of Life Questionnaire
Core-30 (EORTC QLQ-C30).219 220
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CONCLUSION
Immunotherapy represents a major breakthrough for the
treatment of advanced HCC, offering some of the first
demonstrated improvements for patient outcomes over
standard-of-care systemic therapies since the late 2000s.
Despite these advances, immunotherapy for HCC is
currently only applicable to patients with advanced-stage
disease and largely not curative in intent. Furthermore,
the question of how to manage disease that progresses
after ICI therapy remains unanswered. Additionally, the
use of immunotherapy for early-stage disease remains
largely investigational. As additional trials continue to
report results, more options may become available for
later lines of therapy. Future trials are needed to address
the impact of immunotherapy in combination strategies with locoregional approaches, to assist oncologists
and their patients in balancing the potential for harm
and benefit in early-
stage cancer. In the future, the
indications for existing therapies are likely to continue
to expand and novel combinations may be approved.
Greten TF, et al. J Immunother Cancer 2021;9:e002794. doi:10.1136/jitc-2021-002794

These guidelines will be updated as the field continues
to develop.
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Panel recommendations
Patient and caregiver education for HCC should
include an overview of the liver’s function in the body,
an explanation of underlying liver diseases such as
HBV, HCV, and NASH, and a discussion of how immunotherapy works to treat their cancer.
►► Patients must know which provider is coordinating
their treatment, and they need to have clear instructions to promptly report any signs or symptoms of
potential immune-related toxicities.
►► Patients need counseling on the goals of treatment in
advanced HCC, which is not curative in most patients,
despite significant advances. Management of HCC
should include focus on supportive care for uncontrolled symptoms and inclusion of palliative care
specialists.
►► Patients should receive education on the expected
toxicities associated with immunotherapies, including
hepatitis, colitis, pneumonitis, and immune-
related
endocrinopathies. Detailed call parameters should be
provided to promptly report signs and symptoms of
irAEs.
►► Assessment of patients’ physical function and symptoms should be performed before, during, and after
therapy.
►► Patients should be referred to a treatment team
including a social worker and a financial manager to
assist in navigating healthcare costs and identifying
support systems.
►► Conversations should be initiated with patients about
how the costs of immunotherapy treatment will be
covered, including contributions from private insurance, Medicare and Medicaid, clinical trials, patient
assistance programs, or compassionate use as needed.
►► Patients should be provided information about local
advocacy and support groups specific to primary liver
cancer.
►►
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